Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Feasibility Study of the FARAFLEX Mapping and PFA System

NCT: NCT06510556 · RECRUITING

NCT IDNCT06510556
StatusRECRUITING
Start Date2025-02-17
Completion2027-09-15
SponsorBoston Scientific Corporation (INDUSTRY)
First posted
Last updated

Brief Summary

The objective of this feasibility study is to evaluate the safety and effectiveness of the FARAFLEX mapping and pulsed field ablation (PFA) catheter, a novel catheter in treating persistent atrial fibrillation (PersAF) or symptomatic Paroxysmal Atrial Fibrillation (PAF).

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑